Pulse Biosciences Inc (PLSE) Financial Statements (2026 and earlier)

Company Profile

Business Address 3957 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments80,73595,214106,349119,279118,03879,033
Cash and cash equivalent80,73595,214106,349119,279118,03879,033
Receivables27415    
Inventory, net of allowances, customer advances and progress billings136575130  
Inventory136575130  
Other undisclosed current assets2,2761,8711,7601,6001,4111,381
Total current assets:83,42197,157108,160120,909119,44980,414
Noncurrent Assets
Operating lease, right-of-use asset6,0106,3166,6076,8897,1636,588
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,0511,0551,1091,0621,1601,221
Intangible asset, including goodwill, after accumulated amortization3,3663,5323,6983,8454,0114,177
Goodwill2,7912,7912,7912,7912,7912,791
Intangible asset, excluding goodwill, after accumulated amortization5757419071,0541,2201,386
Other noncurrent assets691705677678677646
Total noncurrent assets:11,11811,60812,09112,47413,01112,632
TOTAL ASSETS:94,539108,765120,251133,383132,46093,046
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,3538,1817,5196,3548,7005,548
Accounts payable2,7772,9782,7422,3701,6731,727
Accrued liabilities3,5765,2034,7773,9847,0273,821
Other undisclosed current liabilities1,5701,5191,4591,4061,3551,193
Total current liabilities:7,9239,7008,9787,76010,0556,741
Noncurrent Liabilities
Liabilities, other than long-term debt5,9606,3716,7867,1717,5437,174
Operating lease, liability5,9606,3716,7867,1717,5437,174
Total noncurrent liabilities:5,9606,3716,7867,1717,5437,174
Total liabilities:13,88316,07115,76414,93117,59813,915
Equity
Equity, attributable to parent80,65692,694104,487118,452114,86279,131
Common stock686867676662
Additional paid in capital543,869538,474530,883525,680505,296450,184
Accumulated deficit(463,281)(445,848)(426,463)(407,295)(390,500)(371,115)
Total equity:80,65692,694104,487118,452114,86279,131
TOTAL LIABILITIES AND EQUITY:94,539108,765120,251133,383132,46093,046

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues26486    
Cost of revenue(260)(279)    
Gross profit:4(193)    
Operating expenses(18,257)(20,174)(20,275)(18,044)(20,261)(13,655)
Operating loss:(18,253)(20,367)(20,275)(18,044)(20,261)(13,655)
Nonoperating income8209821,1071,249876975
Interest and debt expense      
Loss from continuing operations before equity method investments, income taxes:(17,433)(19,385)(19,168)(16,795)(19,385)(12,680)
Other undisclosed income from continuing operations before income taxes 145,581     
Net income (loss):128,148(19,385)(19,168)(16,795)(19,385)(12,680)
Other undisclosed net income (loss) attributable to parent(145,581)     
Net loss available to common stockholders, diluted:(17,433)(19,385)(19,168)(16,795)(19,385)(12,680)

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income (loss):128,148(19,385)(19,168)(16,795)(19,385)(12,680)
Comprehensive income (loss):128,148(19,385)(19,168)(16,795)(19,385)(12,680)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(145,581)     
Comprehensive loss, net of tax, attributable to parent:(17,433)(19,385)(19,168)(16,795)(19,385)(12,680)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: